{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Dose limiting toxicity will be accessed based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","groups":[{"description":"100 mg/m\\^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.\n\nLenalidomide\n\nnab-paclitaxel","id":"OG000","title":"Lenalidomide and Nab-paclitaxel"}],"populationDescription":"Results were not analyzed due to lack of sufficient data. PI left the institution.","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Maximum Tolerated Dose (Phase I)","type":"PRIMARY"}